FFA
BBH icon

Freedman Financial Associates’s VanEck Biotech ETF BBH Stock Holding History

Freedman Financial Associates’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-70
Closed -$12K – 43
2022
Q1 		$12K Buy
+70
New +$11.3K 0.01% 337

Other funds holding BBH

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TIA
Traphagen Investment Advisors Oradell, New Jersey $1.4B AUM 19.32% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MJRIC
Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return
MCM
Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

Freedman Financial Associates's BBH Position: Q2 2022 in Review

Freedman Financial Associates sold out of VanEck Biotech ETF (BBH) in Q2 2022, closing a stake of 70 shares — an estimated $12K sold.

Freedman Financial Associates first reported a position in BBH in Q1 2022 and held it in 1 quarter. The position peaked at $12K in Q1 2022. 108 funds tracked by Wall St. Rank hold BBH as of Q2 2022.

  • Freedman Financial Associates reported no remaining VanEck Biotech ETF position as of Q2 2022 after selling out during the quarter.
  • Freedman Financial Associates sold 70 VanEck Biotech ETF shares in Q2 2022, an estimated $12K.
  • Freedman Financial Associates first reported a position in VanEck Biotech ETF in Q1 2022 and held it in 1 quarter.
  • Freedman Financial Associates's VanEck Biotech ETF position peaked at $12K in Q1 2022.
  • 108 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2022.

Based on Freedman Financial Associates's 13F filing for Q2 2022.